Search

everythinglearnresearchcommunity

for

Search:↓

Compound 4 is a promising treatment for hair loss with low toxicity.

New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.

New androgen receptor modulators show promise for treating diseases like prostate cancer and muscle wasting.

New treatments for prostate cancer and BPH show promise, including novel compounds that target hormone synthesis and response.

Analog 23 is a promising compound for prostate cancer treatment.

A compound made by Pfizer can potentially stimulate hair growth and reduce oil production, making it a good candidate for topical use.

Researchers created a new, efficient way to make Dutasteride, a hair loss and prostate drug, with high purity using a benzoyl group.

Certain changes to the B-ring of androgen receptor ligands can increase their effectiveness for potential treatments of muscle and bone conditions.

Flutamide effectively treats female pattern hair loss with low doses showing good liver tolerance.

A new, less toxic and more efficient method to create the anti-baldness compound RU58841 was developed in 2014.

Enobosarm significantly increased muscle mass and improved physical function in elderly men and postmenopausal women without serious side effects.

Both drugs lower DHT levels, with GI198745 being more effective.

Fluridil promotes hair growth safely and effectively for androgenetic alopecia.

Retinoids increase steroid sulfatase activity in leukemia cells through RARα/RXR and involves certain pathways like phosphoinositide 3-kinase and ERK-MAP kinase.

New tests detect finasteride and dutasteride in urine quickly and easily.

Different drugs can treat high male hormone levels in women, but they have various effects and some may harm a fetus.

Low-dose flutamide improved hirsutism and satisfaction in women but had common side effects, causing some to stop treatment.

Certain inhibitors slow down plant growth by causing early cell specialization without changing the cell development pattern.

GI198745 is more potent and longer-lasting than finasteride, potentially better for treating hair loss.

New research is needed to create better drugs that block the enzyme responsible for conditions like male baldness and prostate enlargement.

Fluridil safely promotes hair growth in men with androgenetic alopecia.

The document shows the state of pharmaceutical patents as of 1999, focusing on treatments for various diseases.

Dutasteride effectively treats benign prostatic obstruction, improves urinary flow, reduces prostate size, and may prevent prostate cancer, but can cause sexual side effects.

Fluridil safely promotes hair growth in men with androgenetic alopecia.

TRP channels in the skin are important for sensation and health, and targeting them could help treat skin disorders.

Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.

The document concludes that targeting 5α-reductase, the androgen receptor, and hair growth genes, along with using compounds with anti-androgenic properties, could lead to more effective hair loss treatments.

5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.

New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.

We need better ways to test and understand SARMs to make safer and more effective treatments.